Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.47 |
| ▸ | RAD52 | P43351 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983701 | 0.85 | KMT2A (0.46) | GRM1KMT2ARAD52RAB9AMAPT | |
| SCHEMBL23460215 | 0.82 | KMT2A (0.50) | GRM1KMT2ARAD52RAB9AMAPT | |
| SCHEMBL1474111 | 0.79 | RAB9A (0.63) | GRM1KMT2ARAB9AMAPTMEN1 | |
| SCHEMBL23460116 | 0.76 | KDM4E (0.57) | GRM1KMT2ARAB9AMAPTMEN1 | |
| SCHEMBL17107193 | 0.74 | KMT2A (0.65) | GRM1KMT2ARAD52RAB9AMEN1 | |
| SCHEMBL23486294 | 0.73 | RAB9A (0.42) | GRM1KMT2ARAD52RAB9AMAPT | |
| SCHEMBL23460138 | 0.71 | RAB9A (0.44) | GRM1KMT2ARAD52RAB9AMAPT | |
| SCHEMBL9481963 | 0.70 | RAB9A (0.62) | GRM1KMT2ARAB9AMAPTMEN1 | |
| SCHEMBL17107155 | 0.69 | GRM1 (0.87) | GRM1KMT2ARAB9AMAPTMEN1 | |
| SCHEMBL17107109 | 0.69 | GRM1 (0.64) | GRM1KMT2ARAD52RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-4069697-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113263-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065034-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | CRHR1, CRH, CRHR2 | GRM1 89/4885KMT2A 4183/4885RAD52 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.